None listed
Conditions
Brief summary
Nasal High Flow (NHF) is the administration of high flows (approximately 70 L.min-1) of gas through nasal prongs. NHF is used to enhance oxygenation patients in respiratory distress and during induction of anaesthesia to extend the safe apnoea time. There are concerns about NHF dislodging and spreading infected respiratory particles and increasing the risk of infection for healthcare workers when treating patients with respiratory illness. Given the reported benefits to patient care of NHF, it would be desirable to understand further the effect that NHF may have on the risk of infection for a healthcare worker. This study aims to: 1. Determine whether a surgical mask is effective in reducing particle emission into the environment with nasal high flow 2. Assess the tolerability of a novel experimental set up for measuring aerosol emissions in patients with COVID-19 or similar respiratory illnesses using healthy adult volunteers and inform sample size calculations for a future study in patients with acute respiratory illness.
Interventions
A member of the research team will fit each participant with a commercially available non-invasive ventilation (NIV) hood attached to a particle counter. Flows of 0, 6, 60 L.min-1 will be administered through a nasal high flow interface i) with and ii) without a surgical mask while the patient is a) breathing, b) speaking and c) coughing.
Readings will be taken for 1 minute per intervention over a single one hour session.
The readings will be taken in a commercial laboratory where a particle cou
A member of the research team will fit each participant with a commercially available non-invasive ventilation (NIV) hood attached to a particle counter. Flows of 0, 6, 60 L.min-1 will be administered through a nasal high flow interface i) with and ii) without a surgical mask while the patient is a) breathing, b) speaking and c) coughing. Readings will be taken for 1 minute per intervention over a single one hour session. The readings will be taken in a commercial laboratory where a particle counter is available. A member of the research team will assist the participant throughout to ensure that the protocol is followed
Sponsors
University of Auckland
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
• Participants 18 years and over • Capable of informed consent • Neck size of 34-52 cm (appropriate to NIV hoods available)
Exclusion criteria
• Diagnosis of COVID-19 within the last 4 weeks • Current symptoms of respiratory illness or COVID-19 • Lung disease (e.g. > mild asthma, COPD, Bronchiectasis) • Mask phobia / claustrophobia • Conditions that are contraindicated by the manufacturer (Fisher & Paykel Healthcare) for using nasal high flow • Direct reports of the principal investigator
Outcome results
None listed